Overview

Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels after meals.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Vildagliptin
Criteria
Inclusion Criteria:

- Blood glucose criteria must be met

- Body mass index (BMI) in the range 23-45

Exclusion Criteria:

- Diagnosis of diabetes

- Serious cardiovascular events within the past 6 months

- Use of insulin or any oral antidiabetic agent

- Other protocol-defined exclusion criteria may apply